Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label study

Basit Öğe Kaydı
dc.contributor.authorErtam I.
dc.contributor.authorMutlu B.
dc.contributor.authorUnal I.
dc.contributor.authorAlper S.
dc.contributor.authorKivçak B.
dc.contributor.authorOzer O.
dc.date.accessioned2019-10-26T23:56:35Z
dc.date.available2019-10-26T23:56:35Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of this study was to compare the effectiveness of gel formulations containing arbutin, synthetic ellagic acid and plant extracts that contain ellagic acid, on patients with melasma. Thirty patients who applied to Ege University Medical Faculty, Department of Dermatology, were included in the study. A signed consent was obtained from each patient prior to study. Patients whose type of melasma was determined via Wood's lamp were randomized to groups of arbutin, synthetic ellagic acid and plant extract containing natural ellagic acid. The pigment density of patients was evaluated via Mexameter before and after the treatment. The approval of the Institutional Ethics Committee of Ege University was obtained before the study. Wilcoxon and Kruskal-Wallis tests were used in the statistical analysis. Nine of 10 patients, for whom synthetic ellagic acid was started, completed the study. A decrease in the level of melanin was determined in eight of these nine patients (P = 0.038). A significant decrease in the level of melanin was also determined in all 10 patients who used plant extract containing ellagic acid (P = 0.05). A significant response was obtained from all of 10 patients who used arbutin. The difference between pre- and post-treatment levels of melanin was statistically significant (P = 0.05). Formulations prepared with plant extracts containing ellagic acid was found effective on melasma, similar to the formulations containing synthetic ellagic acid and arbutin. This material that is not yet being used widespread commercially on melasma could be an effective alternative for treatment of melasma. © 2008 Japanese Dermatological Association.en_US
dc.identifier.doi10.1111/j.1346-8138.2008.00522.xen_US
dc.identifier.endpage574en_US
dc.identifier.issn0385-2407
dc.identifier.issue9en_US
dc.identifier.pmid18837701en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage570en_US
dc.identifier.urihttps://doi.org/10.1111/j.1346-8138.2008.00522.x
dc.identifier.urihttps://hdl.handle.net/11454/20836
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectArbutinen_US
dc.subjectEllagic aciden_US
dc.subjectMelasmaen_US
dc.subjectTreatmenten_US
dc.titleEfficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu